Fresenius Reports Q3 2026 Financial Results Exceeding Analyst Expectations

Fresenius reported third-quarter 2026 organic growth of 5% to €5.8 billion. EBIT before special items rose 10% on a currency-adjusted basis to €638 million, exceeding the €619 million analyst consensus, while the EBIT margin increased to 11.0% from 10.5% a year earlier. Fresenius Kabi’s EBIT margin reached 17.0%, within its 17%–19% target range, and the biopharma, medtech and nutrition businesses together increased EBIT by 27% on a currency-adjusted basis.